Table 5.
Treatment-related adverse events (TEAEs) experienced by patients in the biosimilar (BG) and original drug (ODG) groups.
| Adverse Event | BG (n=606) | ODG (n=452) |
|---|---|---|
| Any Grade | Grade 3-4 | |
| Total Patients | % | |
| Fatigue | 57 | 9.26% |
| Fever | 47 | 7.91% |
| Pneumonia | 8 | 2.27% |
| Anemia | 70 | 9.15% |
| Leukopenia | 17 | 2.93% |
| Neutropenia | 58 | 8.87% |
| Thrombocytopenia | 37 | 5.16% |
| Hypertension | 38 | 3.34% |
| Bleeding | 20 | 2.07% |
| Thromboembolism | 4 | 0.43% |
Adverse events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.